[go: up one dir, main page]

DE60106968T2 - Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren - Google Patents

Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren Download PDF

Info

Publication number
DE60106968T2
DE60106968T2 DE60106968T DE60106968T DE60106968T2 DE 60106968 T2 DE60106968 T2 DE 60106968T2 DE 60106968 T DE60106968 T DE 60106968T DE 60106968 T DE60106968 T DE 60106968T DE 60106968 T2 DE60106968 T2 DE 60106968T2
Authority
DE
Germany
Prior art keywords
alkyl
pyrimidin
alkoxy
ethanol
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60106968T
Other languages
German (de)
English (en)
Other versions
DE60106968D1 (de
Inventor
Banavara Lakshman Eastern Point Road Groton MYLARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60106968D1 publication Critical patent/DE60106968D1/de
Application granted granted Critical
Publication of DE60106968T2 publication Critical patent/DE60106968T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60106968T 2000-11-30 2001-11-19 Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren Expired - Fee Related DE60106968T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
US250069P 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
DE60106968D1 DE60106968D1 (de) 2004-12-09
DE60106968T2 true DE60106968T2 (de) 2005-11-03

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60106968T Expired - Fee Related DE60106968T2 (de) 2000-11-30 2001-11-19 Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren

Country Status (38)

Country Link
US (1) US6544998B2 (es)
EP (1) EP1337271B1 (es)
JP (1) JP2004514699A (es)
KR (1) KR20030059290A (es)
CN (1) CN1477975A (es)
AP (1) AP2001002360A0 (es)
AR (1) AR031431A1 (es)
AT (1) ATE281181T1 (es)
AU (1) AU2002215159A1 (es)
BG (1) BG107774A (es)
BR (1) BR0115783A (es)
CA (1) CA2430298A1 (es)
CR (1) CR6964A (es)
CZ (1) CZ20031399A3 (es)
DE (1) DE60106968T2 (es)
DO (1) DOP2001000289A (es)
EA (1) EA200300432A1 (es)
EC (1) ECSP034624A (es)
EE (1) EE200300248A (es)
ES (1) ES2230378T3 (es)
HR (1) HRP20030420A2 (es)
HU (1) HUP0302160A3 (es)
IL (1) IL155704A0 (es)
IS (1) IS6786A (es)
MA (1) MA26964A1 (es)
MX (1) MXPA03004870A (es)
NO (1) NO20032441L (es)
OA (1) OA12534A (es)
PA (1) PA8534101A1 (es)
PE (1) PE20020597A1 (es)
PL (1) PL365927A1 (es)
PT (1) PT1337271E (es)
SK (1) SK6192003A3 (es)
SV (1) SV2003000751A (es)
TN (1) TNSN01169A1 (es)
UY (1) UY27042A1 (es)
WO (1) WO2002043762A2 (es)
ZA (1) ZA200303381B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
CZ299755B6 (cs) * 2001-05-25 2008-11-12 Warner-Lambert Company Llc Kapalná farmaceutická kompozice obsahující analoggama-aminomáselné kyseliny, zpusob její prípravy a použití
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
EP1729740A2 (en) * 2004-04-02 2006-12-13 Impax Laboratories, Inc. PHARMACEUTICAL DOSAGE FORMS HAVING IMMEDIATE RELEASE AND/OR CONTROLLED RELEASE PROPERTIES THAT CONTAIN A GABA<SB>B</SB> RECEPTOR AGONIST
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
KR101063663B1 (ko) 2005-02-17 2011-09-07 아스텔라스세이야쿠 가부시키가이샤 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
MY148657A (en) 2007-04-27 2013-05-15 Purdue Pharma Lp Trpv1 antagonists and uses thereof
AU2008310114B2 (en) * 2007-10-09 2014-01-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CN103228142A (zh) * 2010-09-28 2013-07-31 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
ES2620528T3 (es) 2011-06-22 2017-06-28 Purdue Pharma Lp Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20220169668A1 (en) 2019-04-17 2022-06-02 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
MX2021013511A (es) * 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
EP0059987B1 (en) 1979-06-01 1985-08-14 The Wellcome Foundation Limited Alpha-cyano-alpha-((n-guanidino)-imino) toluenes
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
ES2215570T3 (es) * 1999-04-01 2004-10-16 Pfizer Products Inc. Compuestos para tratar y prevenir complicaciones diabeticas.
TR200102810T2 (tr) * 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler

Also Published As

Publication number Publication date
SK6192003A3 (en) 2004-07-07
JP2004514699A (ja) 2004-05-20
AR031431A1 (es) 2003-09-24
IL155704A0 (en) 2003-11-23
PT1337271E (pt) 2005-01-31
ES2230378T3 (es) 2005-05-01
UY27042A1 (es) 2002-07-31
EE200300248A (et) 2003-10-15
MXPA03004870A (es) 2003-08-19
PA8534101A1 (es) 2002-10-31
WO2002043762A2 (en) 2002-06-06
HUP0302160A2 (hu) 2003-11-28
DE60106968D1 (de) 2004-12-09
TNSN01169A1 (fr) 2005-11-10
CZ20031399A3 (cs) 2004-04-14
US6544998B2 (en) 2003-04-08
PL365927A1 (en) 2005-01-10
ATE281181T1 (de) 2004-11-15
PE20020597A1 (es) 2002-07-08
US20020091128A1 (en) 2002-07-11
KR20030059290A (ko) 2003-07-07
ECSP034624A (es) 2003-07-25
ZA200303381B (en) 2004-04-30
CN1477975A (zh) 2004-02-25
SV2003000751A (es) 2003-01-13
BR0115783A (pt) 2003-09-16
AP2001002360A0 (en) 2001-12-31
NO20032441D0 (no) 2003-05-28
OA12534A (en) 2006-06-05
IS6786A (is) 2003-04-14
HUP0302160A3 (en) 2005-05-30
BG107774A (en) 2004-01-30
AU2002215159A1 (en) 2002-06-11
WO2002043762A3 (en) 2003-03-13
MA26964A1 (fr) 2004-12-20
DOP2001000289A (es) 2003-02-15
NO20032441L (no) 2003-07-03
EP1337271B1 (en) 2004-11-03
HRP20030420A2 (en) 2004-08-31
CA2430298A1 (en) 2002-06-06
CR6964A (es) 2004-02-02
EA200300432A1 (ru) 2003-10-30
EP1337271A2 (en) 2003-08-27

Similar Documents

Publication Publication Date Title
DE60106968T2 (de) Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
DE69231395T3 (de) Neue medizinische Indikation für Tachykinin-Antagonisten
DE3650488T2 (de) Verwendung eines Tetrahydrocarbazolonderivates zur Herstellung von Arzneimitteln
EP1477166B1 (de) Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
DE69929440T2 (de) Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
DE69833671T2 (de) KOMBINATION AUS EINEM ALPHA-1-ADRENOREZEPTOR ANTAGONISTEN UND EINEM CGM PDEv HEMMER ZUR BEHANDLUNG VON IMPOTENZ
DE69725345T2 (de) Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden
DE3752062T2 (de) Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
DE19953414A1 (de) Imidazopyridinderivate als Phospodiesterase VII-Hemmer
DE60117716T2 (de) Verfahren zur Erhöhung der Bioverfügbarkeit von Azithromycin
CH686867A5 (de) Arzneimittelkompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu ihrer Herstellung.
DE69424156T2 (de) Arzneimittel zur prophylaxe und behandlung von katarakt
DE69826561T2 (de) Aldose Reductase Hemmung zur Vorbeugung oder zur Umkehrung der diabetischen Kardiomyopathie
DE60212710T2 (de) Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid
DE69432626T2 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
DE60204694T2 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
WO1998016224A1 (de) Pyrazolinone zur behandlung von potenzstörungen
EP0314984B1 (de) Verwendung von 2-Pyrimidinyl-1-piperazin-Derivaten
DD242749A5 (de) Verbesserte entzuendungshemmende zusammensetzungen und verfahren
CN101686673B (zh) 用化学治疗药剂与放射的组合治疗瘤形成的方法
DE3779991T2 (de) Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.
DE19929031A1 (de) Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
DE69307197T2 (de) Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis
WO2000032199A1 (de) Verwendung von galanthamin und galanthaminderivaten bei akuten funktionellen hirnschäden
DD298052A5 (de) Verwendung von alkylphosphorsaeure-verbindungen zur bekaempfung von psoriasis-erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee